GENETIC ANALYSIS NK -60 Net Assets
GENETIC ANALYSIS NK -60 net assets. Based on the latest financial reports, GENETIC ANALYSIS NK -60 (8V8) has net assets worth €20.71 Million EUR (≈ $24.22 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€44.64 Million ≈ $52.19 Million USD) and total liabilities (€23.93 Million ≈ $27.97 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 8V8 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €20.71 Million |
| % of Total Assets | 46.4% |
| Annual Growth Rate | -21.71% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 23.07 |
Net Assets of GENETIC ANALYSIS NK -60 (2021–2025)
Net assets of GENETIC ANALYSIS NK -60 from 2021 to 2025. This chart illustrates how GENETIC ANALYSIS NK -60's net assets have evolved over time, based on quarterly financial data. See GENETIC ANALYSIS NK -60 (8V8) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for GENETIC ANALYSIS NK -60 (2021–2025)
The table below shows the annual net assets of GENETIC ANALYSIS NK -60 from 2021 to 2025. For live market cap and overall valuation, see 8V8 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €27.08 Million ≈ $31.66 Million |
+20.39% |
| 2024-12-31 | €22.49 Million ≈ $26.30 Million |
-29.70% |
| 2023-12-31 | €32.00 Million ≈ $37.41 Million |
-27.51% |
| 2022-12-31 | €44.14 Million ≈ $51.60 Million |
-38.77% |
| 2021-12-31 | €72.09 Million ≈ $84.28 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to GENETIC ANALYSIS NK -60's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2618200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
GENETIC ANALYSIS NK -60 Net Assets Breakdown (December 2025)
GENETIC ANALYSIS NK -60 net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €53.26 Million | 196.69% |
| Total Equity | €27.08 Million | 100.00% |
GENETIC ANALYSIS NK -60 Competitors by Market Cap
The table below lists competitors of GENETIC ANALYSIS NK -60 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Adagio Medical Holdings, Inc Common Stock
NASDAQ:ADGM
|
$2.37 Million |
|
Lexus Granito (India) Limited
NSE:LEXUS
|
$2.37 Million |
|
Vast Renewables Limited Ordinary Shares
NASDAQ:VSTE
|
$2.37 Million |
|
Tristel
LSE:TSTL
|
$2.37 Million |
|
Svenska Aerogel Holding AB (publ)
ST:AERO
|
$2.36 Million |
|
Golden Goliath Resources Ltd.
V:GNG
|
$2.36 Million |
|
Discovery Alaska Ltd
AU:DAF
|
$2.36 Million |
|
Silver Castle Holdings Ltd
TA:SLCL
|
$2.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GENETIC ANALYSIS NK -60's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 22,493,000 to 27,079,000, a change of 4,586,000 (20.4%).
- Net loss of 11,413,000 reduced equity.
- New share issuances of 16,945,000 increased equity.
- Other factors decreased equity by 946,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-11.41 Million | -42.15% |
| Share Issuances | €16.95 Million | +62.58% |
| Other Changes | €-946.00K | -3.49% |
| Total Change | €- | 20.39% |
Book Value vs Market Value Analysis
This analysis compares GENETIC ANALYSIS NK -60's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.08x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €2.75 | €0.03 | x |
| 2022-12-31 | €1.68 | €0.03 | x |
| 2023-12-31 | €0.80 | €0.03 | x |
| 2024-12-31 | €0.44 | €0.03 | x |
| 2025-12-31 | €0.39 | €0.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GENETIC ANALYSIS NK -60 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -42.15%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -68.29%
- • Asset Turnover: 0.32x
- • Equity Multiplier: 1.94x
- Recent ROE (-42.15%) is above the historical average (-57.31%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -40.23% | -426.57% | 0.08x | 1.16x | €-36.21 Million |
| 2022 | -64.05% | -253.28% | 0.17x | 1.46x | €-32.69 Million |
| 2023 | -74.44% | -168.36% | 0.26x | 1.67x | €-27.02 Million |
| 2024 | -65.66% | -92.97% | 0.37x | 1.88x | €-17.02 Million |
| 2025 | -42.15% | -68.29% | 0.32x | 1.94x | €-14.12 Million |
Industry Comparison
This section compares GENETIC ANALYSIS NK -60's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $3,811,235,250
- Average return on equity (ROE) among peers: -36.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GENETIC ANALYSIS NK -60 (8V8) | €20.71 Million | -40.23% | 1.16x | $2.36 Million |
| IZOTROPIC CORP. (1R3) | $-3.85 Million | 0.00% | 0.00x | $6.11 Million |
| ALPHAHELIX MOL.DIAGN. SK1 (4MB) | $4.18 Million | -188.49% | 2.68x | $839.64K |
| HANGZHOU TIGERMED CO. H 1 (5HZ1) | $24.45 Billion | 8.28% | 0.21x | $604.57 Million |
| Check-Cap Ltd (7CC) | $16.38 Million | -84.54% | 0.20x | $9.20 Million |
| INTERGRATED DIA.H DL 025 (8I8) | $3.50 Billion | 30.79% | 1.04x | $251.46 Million |
| GENINCODE PLC LS -01 (9PL) | $7.90 Million | -70.37% | 0.49x | $5.28 Million |
| INOVIQ LTD. (EGQ0) | $28.29 Million | -64.31% | 0.09x | $13.50 Million |
| Eurofins Scientific SE (ESF0) | $4.68 Billion | 16.73% | 1.00x | $11.18 Billion |
| ICON Public Limited Company (IJF) | $1.62 Billion | 23.11% | 0.80x | $7.52 Billion |
About GENETIC ANALYSIS NK -60
Genetic Analysis AS, a science-based diagnostic company, engages in the research, development, manufacturing, and sale of diagnostic test solutions for human microbiome in the United States, Europe, and internationally. The company offers GA-map MHI Gut Health Test, a microbiome-based diagnostic test for antibiotic-induced microbiome imbalances; GA-map Dysbiosis Test, a diagnostic microbiome test… Read more